



Black Diamond Therapeutics to Present at Upcoming Investor Conferences

November 08, 2021

CAMBRIDGE, Mass. and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company's progress at the following upcoming investor conferences:

- The Stifel 2021 Virtual Healthcare Conference. The corporate presentation will take place on Monday, November 15, 2021 at 4:40 PM ET.
- The 2021 Jefferies London Healthcare Conference. The presentation will be available on-demand beginning Thursday, November 18, 2021, starting at 4:00 AM ET.

A webcast of the Stifel presentation can be accessed by visiting the investor relations section of the Company's website, www.blackdiamondtherapeutics.com. A replay of each presentation will also be available and archived on the site for 30 days.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform and drug discovery engine, the Mutation-Allosteric-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:

Natalie Wildenradt

investors@bdtx.com

For Media:

Kathy Vincent

(310) 403-8951

media@bdtx.com